Larimar Therapeutics (STU:ZA71) Short Interest


STU:ZA71 Larimar Therapeutics Inc STU:ZA71
34 GF Score
Price €3.16
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:ZA71 vs GLSI, RGNX, PBYI: Short Interest Comparison

For the Biotechnology subindustry, Larimar Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Larimar Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's Short Interest falls into.


STU:ZA71
34GF Score
Larimar Therapeutics Inc STU:ZA71
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Larimar Therapeutics Business Description

Other Exchanges LRMR:USAZA71:Germany
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score

Get the complete analysis for STU:ZA71

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.16
Price